TORONTO, October 31, 2025 — Leads & Copy — Edesa Biotech, Inc. (Nasdaq:EDSA) will participate in upcoming conferences. Management and business development staff will attend BIO-Europe in Vienna, Austria, November 3-5, 2025, and LSX Investival Showcase Europe in London, UK, November 17, 2025, with a presentation at 3:45 pm GMT.
To schedule a meeting with Edesa, contact conference organizers or email investors@edesabiotech.com.
Edesa Biotech is focused on developing host-directed therapeutics for immuno-inflammatory diseases. Its pipeline includes EB06 for vitiligo, EB01 for allergic contact dermatitis, and paridiprubart for acute respiratory distress syndrome, with funding from the Government of Canada and evaluation in a U.S. government-funded study. Edesa is also pursuing uses for paridiprubart in chronic respiratory diseases.
Sign up for news alerts and connect with Edesa on X and LinkedIn.
Contact: investors@edesabiotech.com
Source: Edesa Biotech, Inc.
